TRIM21 and interstitial lung disease: By chi-square test, patients in the pSS-ILD group had a higher rate of anti-Ro52+ and a lower rate of anti-centromere+ than those in the pSS-non-ILD group, and the differences between the two groups were statistically significant (p < 0.05) (Table 1).